Table 2.
Patient characteristics and exposure to regorafenib treatment
| N = 47 | |
|---|---|
| Gender, n % | |
| Male | 26 (55) |
| Female | 21 (45) |
| Age (years), median [range] | 81 [63–89] |
| ECOG PS, n % | |
| 0 | 5 (11) |
| 1 | 25 (56) |
| 2 | 17 (36) |
| Frailty criteria, n % | |
| Dependence for daily activities | 8 (17) |
| History of comorbidities | 13 (28) |
| Geriatric symptoms | 6 (13) |
| Dependence + Comorbidities | 8 (17) |
| Dependence + Geriatric features | 6 (13) |
| Comorbidities + Geriatric Features | 2 (4.3) |
| Dependence + Geriatric Features + Comorbidities | 4 (8.5) |
| Primary tumor site, n % | |
| Colon | 32 (68) |
| Rectum | 14 (30) |
| Both | 1 (2.1) |
| Metastatic at first diagnosis, n % | 30 (64) |
| Metastatic sites, n % | |
| Liver | 31 (66) |
| Lung | 29 (62) |
| Peritoneum | 11 (23) |
| Bone | 1 (2.1) |
| Number of organs involved by M1 disease, n % | |
| 1 | 17 (36) |
| 2 | 14 (30) |
| 3 | 12 (25) |
| 4 | 2 (4.3) |
| 5 | 2 (4.3) |
| Prior surgery, n % | 31 (66) |
| Prior radiation therapy, n % | 6 (13) |
| Prior adjuvant chemotherapy, n % | 7 (15) |
| Capecitabine alone | 4 (0.8) |
| Capecitabine-oxaliplatin | 3 (0.6) |
| Exposure to regorafenib | |
| Dose intensity (mg/day), median [range] | 91 [58–121] |
| Relative dose intensity (mg/day/theoretical total dose), % [range] | 0.76 [0.48–1.01] |